Evidence-based public policy making for medicines across countries: findings and implications for the future

被引：30

作者：

Godman, Brian ^{[1
,2
,3
,4
]}

Fadare, Joseph ^{[5
,6
]}

Kwon, Hye-Young ^{[7
]}

Dias, Carolina Zampirolli ^{[8
]}

Kurdi, Amanj ^{[1
,3
,9
]}

Dias Godoi, Isabella Piassi ^{[10
,11
]}

Kibuule, Dan ^{[12
]}

Hoxha, Iris ^{[13
]}

Opanga, Sylvia ^{[14
]}

Saleem, Zikria ^{[15
]}

Bochenek, Tomasz ^{[16
]}

Markovic-Pekovic, Vanda ^{[17
]}

Mardare, Ileana ^{[18
]}

Kalungia, Aubrey C. ^{[19
]}

Campbell, Stephen ^{[20
,21
]}

Allocati, Eleonora ^{[22
]}

Pisana, Alice ^{[23
]}

Martin, Antony P. ^{[24
]}

Meyer, Johanna C. ^{[3
]}

机构：

[1] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow G4 0RE, Lanark, Scotland

[2] Karolinska Univ Hosp Huddinge, Karolinska Inst, Div Clin Pharmacol, SE-14186 Stockholm, Sweden

[3] Sefako Makgatho Hlth Sci Univ, Sch Pharm, Pretoria, South Africa

[4] Univ Sains Malaysia, Sch Pharmaceut Sci, George Town, Malaysia

[5] Ekiti State Univ, Dept Pharmacol & Therapeut, Ado Ekiti, Nigeria

[6] Ekiti State Univ Teaching Hosp, Dept Med, Ado Ekiti, Nigeria

[7] Mokwon Univ, Div Biol & Publ Hlth, Daejeon, South Korea

[8] Univ Fed Minas Gerais, Grad Program Publ Hlth, Belo Horizonte, MG, Brazil

[9] Hawler Med Univ, Coll Pharm, Dept Pharmacol, Erbil, Iraq

[10] Univ Fed Sudeste Para, Inst Hlth & Biol Studies, Ave Ipes S-N,Cidade Univ,Cidade Jardim, Maraba, Para, Brazil

[11] Univ Fed Sudeste Para, Grp CNPq Epidemiol Econ & Pharmacol Studies Arb, Avenida Ipes S-N,Cidade Univ,Cidade Jardim, Maraba, Para, Brazil

[12] Univ Namibia, Fac Hlth Sci, Dept Pharm Practice & Policy, Windhoek, Namibia

[13] Univ Med Tirana, Fac Med, Dept Pharm, Tirana, Albania

[14] Univ Nairobi, Sch Pharm, Dept Pharmaceut & Pharm Practice, Nairobi, Kenya

[15] Univ Lahore, Fac Pharm, Lahore, Pakistan

[16] Jagiellonian Univ Med Coll, Fac Hlth Sci, Dept Nutr & Drug Res, Krakow, Poland

[17] Univ Banja Luka, Fac Med, Dept Social Pharm, Banja Luka, Srpska, Bosnia & Herceg

[18] Carol Davila Univ Med & Pharm, Bucharest, Romania

[19] Univ Zambia, Dept Pharm, Lusaka, Zambia

[20] Univ Manchester, Div Populat Hlth Hlth Serv Res & Primary Care, Ctr Primary Care, Manchester M13 9PL, Lancs, England

[21] Univ Manchester, Sch Hlth Sci, NIHR Greater Manchester Patient Safety Translat, Manchester, Lancs, England

[22] Ist Ric Farmacol Mario Negri IRCCS, Milan, Italy

[23] Karolinska Inst, Dept Global Publ Hlth, Stockholm, Sweden

[24] Univ Liverpool, Fac Hlth & Life Sci, Brownlow Hill, Liverpool L69 3BX, Merseyside, England

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2021年 / 10卷 / 12期

关键词：

antimicrobials; biosimilars; COVID-19; demand-side measures; generics; guidelines; managed entry; oncology; orphan medicines; quality indicators; statins; EMERGING HEALTH TECHNOLOGIES; ANGIOTENSIN PRESCRIBING EFFICIENCY; MANAGED ENTRY AGREEMENTS; ATYPICAL ANTIPSYCHOTIC-DRUGS; RESPIRATORY-TRACT INFECTIONS; PROTON PUMP INHIBITORS; ONGOING INITIATIVES; CARDIOVASCULAR-DISEASE; GENERIC SUBSTITUTION; MULTIPLE INITIATIVES;

D O I：

10.2217/cer-2020-0273

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence of non-communicable diseases (NCDs) and new premium priced medicines for cancer, orphan diseases and other complex areas. This is difficult to sustain without reforms. Methods: Extensive narrative review of published papers and contextualizing the findings to provide future guidance. Results: New models are being introduced to improve the managed entry of new medicines including managed entry agreements, fair pricing approaches and monitoring prescribing against agreed guidance. Multiple measures have also successfully been introduced to improve the prescribing of established medicines. This includes encouraging greater prescribing of generics and biosimilars versus originators and patented medicines in a class to conserve resources without compromising care. In addition, reducing inappropriate antibiotic utilization. Typically, multiple measures are the most effective. Conclusion: Multiple measures will be needed to attain and retain universal healthcare.

引用

页码：1019 / 1052

页数：34

共 347 条

[1] Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings [J].